Dr. Sartor on the Science of Sipuleucel-T for Prostate Cancer

Oliver Sartor, MD
Published: Thursday, Aug 17, 2017



Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the science behind the results of a study investigating sipuleucel-T (Provenge) for patients with castration-resistant prostate cancer (CRPC).

There are 2 basic theses that could proposed for the results of this study, explains Sartor. The first is that the immune system is reacting more appropriately in African Americans—meaning the immune system in African Americans is more effective at slowing cancer growth.

The other hypothesis is the tumors present in African Americans might be more prone to being attacked by the immune system, states Sartor. These 2 hypotheses could be combined. It could be better immune systems and more responsive tumors, but none of this has been tested yet.
 


Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the science behind the results of a study investigating sipuleucel-T (Provenge) for patients with castration-resistant prostate cancer (CRPC).

There are 2 basic theses that could proposed for the results of this study, explains Sartor. The first is that the immune system is reacting more appropriately in African Americans—meaning the immune system in African Americans is more effective at slowing cancer growth.

The other hypothesis is the tumors present in African Americans might be more prone to being attacked by the immune system, states Sartor. These 2 hypotheses could be combined. It could be better immune systems and more responsive tumors, but none of this has been tested yet.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x